Market Cap 1.57B
Revenue (ttm) 235.13M
Net Income (ttm) 5.75M
EPS (ttm) N/A
PE Ratio 22.71
Forward PE 18.83
Profit Margin 2.45%
Debt to Equity Ratio 0.00
Volume 1,673,870
Avg Vol 1,562,484
Day's Range N/A - N/A
Shares Out 131.63M
Stochastic %K 93%
Beta 1.25
Analysts Strong Sell
Price Target $11.71

Company Profile

Aurinia Pharmaceuticals Inc. is a biopharmaceutical company that engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs. It offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. The company also develops AUR200, a dual inhibitor of B cell activating factor and a proliferation inducing ligand for the potential treatment of autoimmune diseases. It has a collaboration and license agreement wit...

Industry: Biotechnology
Sector: Healthcare
Phone: 250 744 2487
Fax: 250 708 4345
Address:
#140, 14315 – 118 Avenue, Edmonton, Canada
US_Bull
US_Bull Oct. 27 at 7:14 PM
$AUPH Patent approval will take this straight through 14$+ in a blink of an eye we are close.
4 · Reply
US_Bull
US_Bull Oct. 27 at 7:12 PM
$AUPH I loaded more today another 1,300 shares.
0 · Reply
GeorgeTitmunchFDA
GeorgeTitmunchFDA Oct. 27 at 7:08 PM
$AUPH The Bull needs to keep charging Right over Skidmark's Ass
0 · Reply
RicardoDelJuego
RicardoDelJuego Oct. 27 at 7:07 PM
$AUPH From the linked poster - further consolidation of Lupkynis's safety efficacy and safety profiles, as well as rebuttal of Tidmarsh's claims.
1 · Reply
Yarrow
Yarrow Oct. 27 at 7:07 PM
$AUPH $15 stock after earnings.
0 · Reply
jdoldnumber7
jdoldnumber7 Oct. 27 at 7:01 PM
$AUPH 1.28M shares traded with 1 hour remaining. Up .40 cents.
1 · Reply
Yarrow
Yarrow Oct. 27 at 6:53 PM
$AUPH Aurinia Pharmaceuticals Advances Lupus Nephritis Study in Young Patients - TipRanks.com https://share.google/QYbrYAjD6LDESSN0P
0 · Reply
BudFox121187
BudFox121187 Oct. 27 at 4:40 PM
$AUPH Loading, All Aboard!
0 · Reply
jdoldnumber7
jdoldnumber7 Oct. 27 at 4:32 PM
$AUPH Passing 900K...
0 · Reply
BABYHAIR
BABYHAIR Oct. 27 at 4:29 PM
$AUPH One more breadcrumb to spark discussion, anyone remember Gilead "sniffing" around Aurinia in late 2023? Interesting to note they have a deal with Galapagos. https://pharmaphorum.com/news/galapagos-drops-plan-split-after-market-developments The proposal also saw a 10-year, $5.1 billion R&D alliance with Gilead Sciences significantly amended, with Galapagos regaining full rights to the pipeline of partnered projects. The company said it would stop working on small-molecule drugs, including TYK2 inhibitor GLPG3667, which is in phase 2 trials for systemic lupus erythematosus (SLE) and dermatomyositis, and seek development partners for these programmes.
1 · Reply
Latest News on AUPH
Aurinia Responds to Now Retracted LinkedIn Post

Sep 29, 2025, 8:27 PM EDT - 27 days ago

Aurinia Responds to Now Retracted LinkedIn Post


Aurinia Pharmaceuticals: Shareholder Pressure And Sales Growth

Apr 26, 2025, 10:54 AM EDT - 6 months ago

Aurinia Pharmaceuticals: Shareholder Pressure And Sales Growth


Aurinia Pharmaceuticals: There's Still Time For Sales Growth

Feb 21, 2025, 4:09 PM EST - 8 months ago

Aurinia Pharmaceuticals: There's Still Time For Sales Growth


3 Biotech Stocks With Notable Insider Buying

Jan 22, 2025, 12:29 PM EST - 9 months ago

3 Biotech Stocks With Notable Insider Buying

AZN COGT JAZZ ONC XBI ZYME


3 Small Biotech Stocks With The 'Big Mo' Right Now

Sep 19, 2024, 12:54 PM EDT - 1 year ago

3 Small Biotech Stocks With The 'Big Mo' Right Now

CORT VRDN


Aurinia Pharmaceuticals: This Recovery Can Continue

Sep 18, 2024, 4:41 AM EDT - 1 year ago

Aurinia Pharmaceuticals: This Recovery Can Continue


Aurinia Announces Board Restructuring

Sep 12, 2024, 4:05 PM EDT - 1 year ago

Aurinia Announces Board Restructuring


Aurinia Pharmaceuticals Appears Undervalued

Jul 5, 2024, 2:10 PM EDT - 1 year ago

Aurinia Pharmaceuticals Appears Undervalued


Aurinia Announces 2024 Annual General Meeting Results

Jun 14, 2024, 12:16 PM EDT - 1 year ago

Aurinia Announces 2024 Annual General Meeting Results


US_Bull
US_Bull Oct. 27 at 7:14 PM
$AUPH Patent approval will take this straight through 14$+ in a blink of an eye we are close.
4 · Reply
US_Bull
US_Bull Oct. 27 at 7:12 PM
$AUPH I loaded more today another 1,300 shares.
0 · Reply
GeorgeTitmunchFDA
GeorgeTitmunchFDA Oct. 27 at 7:08 PM
$AUPH The Bull needs to keep charging Right over Skidmark's Ass
0 · Reply
RicardoDelJuego
RicardoDelJuego Oct. 27 at 7:07 PM
$AUPH From the linked poster - further consolidation of Lupkynis's safety efficacy and safety profiles, as well as rebuttal of Tidmarsh's claims.
1 · Reply
Yarrow
Yarrow Oct. 27 at 7:07 PM
$AUPH $15 stock after earnings.
0 · Reply
jdoldnumber7
jdoldnumber7 Oct. 27 at 7:01 PM
$AUPH 1.28M shares traded with 1 hour remaining. Up .40 cents.
1 · Reply
Yarrow
Yarrow Oct. 27 at 6:53 PM
$AUPH Aurinia Pharmaceuticals Advances Lupus Nephritis Study in Young Patients - TipRanks.com https://share.google/QYbrYAjD6LDESSN0P
0 · Reply
BudFox121187
BudFox121187 Oct. 27 at 4:40 PM
$AUPH Loading, All Aboard!
0 · Reply
jdoldnumber7
jdoldnumber7 Oct. 27 at 4:32 PM
$AUPH Passing 900K...
0 · Reply
BABYHAIR
BABYHAIR Oct. 27 at 4:29 PM
$AUPH One more breadcrumb to spark discussion, anyone remember Gilead "sniffing" around Aurinia in late 2023? Interesting to note they have a deal with Galapagos. https://pharmaphorum.com/news/galapagos-drops-plan-split-after-market-developments The proposal also saw a 10-year, $5.1 billion R&D alliance with Gilead Sciences significantly amended, with Galapagos regaining full rights to the pipeline of partnered projects. The company said it would stop working on small-molecule drugs, including TYK2 inhibitor GLPG3667, which is in phase 2 trials for systemic lupus erythematosus (SLE) and dermatomyositis, and seek development partners for these programmes.
1 · Reply
US_Bull
US_Bull Oct. 27 at 3:59 PM
$AUPH This is Tangs latest GLPG, AUPH, and VERA holdings. VERA also has a dual APRIL, BAFF blocker. Could easily see Tang merge us either with GLPG (probably more probably) or with VERA also working with kidney diseases their drug will soon be approved for IgA our market caps more or less are the similar. Both VERA (kidney) and GLPG are heavily involved with inflammatory diseases.
1 · Reply
BABYHAIR
BABYHAIR Oct. 27 at 3:48 PM
$AUPH Galapagos down today creeping towards $2B market cap. I imagine a merger with a 50/50 stock split comes out to about $15 per AUPH share. Not what most would want but a gain is a gain
1 · Reply
BuckeyeInvestor
BuckeyeInvestor Oct. 27 at 3:47 PM
$AUPH blow me Tidmarsh
0 · Reply
bryantboy99
bryantboy99 Oct. 27 at 3:41 PM
0 · Reply
paperjam
paperjam Oct. 27 at 3:33 PM
$AUPH https://pbs.twimg.com/media/G4Ht7YPXQAAMV-e?format=jpg&name=4096x4096
2 · Reply
Auphiliate
Auphiliate Oct. 27 at 3:32 PM
$AUPH Getting ready for a big jump! 😊
0 · Reply
jdoldnumber7
jdoldnumber7 Oct. 27 at 3:30 PM
$AUPH Passing 600K shares traded. Looking like volume is returning!
0 · Reply
joemist1
joemist1 Oct. 27 at 3:29 PM
$AUPH Good morning motha fcking bstrds, make me rich here! You bstrds.
0 · Reply
ATzmansto
ATzmansto Oct. 27 at 3:28 PM
$AUPH It seems to have no problem dropping 10 % in a day...HOW ABOUT we finally go up 10% in a day.
0 · Reply
Amber_Turd
Amber_Turd Oct. 27 at 3:19 PM
$AUPH the question is does Q3 ER bring us back to an ATH?? Leadership owes us an explanation on why we have not rebounded after the Tidmarsh hitpiece!
2 · Reply
raylin
raylin Oct. 27 at 3:11 PM
$AUPH Cmon $30!!! Tang, Pig, Santa, Loch Ness Monster - someone, anyone, sell this MOFO!
0 · Reply
3D_STOCK_TRADING
3D_STOCK_TRADING Oct. 27 at 3:08 PM
$AUPH somebody needs to plug in the bots.
0 · Reply